HB Tort Notes Archives

Drug & Device Defense Forum | Oct. 15, 2018 | New York

May 13th, 2018|Categories: HB Tort Notes, Tort Litigation|Tags: Attorney Ethics, CLE, cyber security, cyber security for medical devices, Dechert, demonstrative evidence, drug liability, FDA approval, FDA guidelines, FDA regulation, FDA warnings, goodell devries, jim frederick, jury presentation, lawyers social media, legal ethics, Litigation Financing, litigation funding, mass torts, medical device breach, Medical Device Litigation, medical devices, megan grossman, michelle yeary, personal jurisdiction, pharmaceutical liability, Product Liability, segal mcambridge|

Sorry! This event has been cancelled. We had a good run for several years but all good things and all that. Look for the sessions to magically appear as part of our new webinar series. --Tom Hagy Emerging legal and business issues facing the pharmaceutical and medical device industries. Conference Chairs Megan Grossman Shareholder Segal McCambridge Singer & Mahoney Ltd. Michelle Hart Yeary Of Counsel Dechert LLP James A. Frederick Partner Goodell DeVries Leech & Dann LLP When Oct. 15, 2018 Where Convene Well&, 151 W 42nd St Times Square, New York Sponsors Hotel Accomodations The Knickerbocker Hotel 6 Times Square, SE corner of 42nd & Broadway Weblink Reservations. $325 Premier King For 3 days pre & post conf reservations, contact Jenny Thorpe | 212-204-4976| jthorne@theknickerbocker.com Ask for "HB Litigation" conference rate. Cut-Off Date: Sept 23 CLE This event will be eligible for CLE Conference Registration Rates • $195 for in-house counsel at pharmaceutical, medical device and insurance companies. • $495 for attorneys in private practice • $395 for attorneys from faculty firms (promo code FAC395) Contact Us (484) 844-0437 Send us an Email Speaking Proposals Send us your idea Ideas@LitigationConferences.com Or go online: Faculty Questions: Faculty@LitigationConferences.com Faculty Dinner | [...]

Class Actions Weekly Roundup from Top Class Actions

March 31st, 2018|Categories: HB Tort Notes|Tags: class actions, facebook class action, facial recognition, mislabeled, top class actions, xarelto|

This roundup is prepared exclusively for HB Litigation Conferences by: Walmart Class Action Claims Glucosamine Tablets are Mislabeled Walmart has been hit with a class action lawsuit claiming that their store brand glucosamine tablets are mislabeled. Plaintiffs Cynthia Parker, Reba Garth, Margaret Herrin, and Shirley Reinhard allege that Walmart misrepresents its store-brand glucosamine sulfate dietary… Read More Sorin 3T Heater Cooler Lawsuit Alleges Serious M. Chimaera Bacterial Infection An Indiana man has filed a Sorin 3T heater cooler lawsuit against LivaNova PLC, alleging their cardiac heater cooler device had caused him to develop a potentially fatal infection. The claimant filed the Sorin 3T heater cooler… Read More Coca-Cola Seeks Dismissal of Diet Coke Class Action Lawsuit Coca-Cola asked a New York federal court to toss a class action lawsuit alleging the company’s use of the name “Diet Coke” is misleading. The company argues that claims against its use of the word “diet” in… Read More Couple Files Stryker Hip Recall Lawsuit Over Metallosis Complications Thousands of hip implants were affected by a Stryker hip recall after they were linked with serious complications, including metallosis. Some patients affected by these major side effects have turned to litigation, hoping to regain some… Read More Facebook Class Action Challenges Facial Recognition Technology Facebook faces a new class action lawsuit alleging that the social media site captured and stored biometric information of non-users [...]

Top Class Actions’ Top Trends Affecting Class Actions in 2018

March 31st, 2018|Categories: HB Tort Notes|Tags: class actions, scott hardy, top class actions|

Editor's Note: This article was written by Kim Gale at Top Class Actions and is reprinted here with the permission of the publisher. Scott Hardy, the company's President & CEO, is one of the speakers featured at HB's Class Action Mastery conference May 9-11, 2018 in New York. Top Class Actions is sponsoring that event and its companion program, Mass Tort Med School, the same week. As we come close to rounding out the first quarter of 2018, it is clear that several class action lawsuit trends from 2017 will continue to ripple through the court system this year. Class Action Lawsuit Stats Did you know three areas are responsible for a third of all class action lawsuits filed in the U.S.? The federal courts in California, Southern District (Miami) of Florida, and the Eastern District (Brooklyn) of New York keep lawyers and judges the busiest. In the initial nine months of 2017, a total 3,136 federal class action lawsuits were filed in those areas alone, according to an article published Dec. 9, 2017 by PorterWright.com. These statistics are apt to change because new Supreme Court decisions (Bristol-Myers Squibb v. Superior Court of California and BNSF Railway Co. v. Tyrrell) rein in a court’s jurisdiction and ability to litigate matters when residents from outside the court’s state make claims. These new decisions mean a defendant [...]

News Release: Law Professors from NYU and Cardozo Among Panelists at Mass Tort Judicial Forum with Hon. Marina Corodemus (ret.)

March 21st, 2018|Categories: HB Tort Notes|Tags: Anderson Kill P.C., Ankura Consulting Group LLC, Arnold & Porter Kaye Scholer LLP, Baron & Budd P.C., Blasingame Burch Garrard & Ashley P.C., BrownGreer PLC, Center for Constitutional Litigation P.C., Corodemus & Corodemus LLC, Drinker Biddle & Reath LLP, Garden City Group LLC, Garretson Resolution Group, Hughes Hubbard & Reed LLP, IBM Cloud, JAMS, Judge Corodemus, Leigh-galese Legal Cost Consulting, Lieff Cabraser Heimann & Bernstein LLP, Mari Henry Leigh & Associates LLC, mass torts, Mass Torts Judicial Forum, Mazie Slater Katz & Freeman LLC, Milberg Tadler Phillips Grossman LLP, Milestone Consulting LLC, professor gilles, professor sharkey, Quinn Emanuel Urquhart & Sullivan LLP, Searcy Denney Scarola Barnhart & Shipley P.A., Sidley Austin LLP, Stroock & Stroock & Lavan LLP, Tanenbaum Keale LLP, the lien resolution group, Verus LLC, Weitz & Luxenberg P.C., Williams & Connolly LLP|

For Immediate Release | Download PDF NEW YORK – MARCH 21, 2018 – Former New Jersey Superior Court Judge Marina Corodemus, now one of the nation's leading special masters for complex litigation, has selected two highly regarded law professors for the faculty of her annual event, Mass Torts Judicial Forum with Hon. Marina Corodemus (ret.), which will take place on April 23, 2018, in New York. Press passes, interviews and program content are available to members of the press. Please contact Tom Hagy at (484) 324-2755 x2070 or write to him at tom.hagy@litigationconferences.com. The professors are: Myriam E. Gilles, Vice Dean and Paul R. Verkuil Chair in Public Law at the Benjamin N. Cardozo School of Law at Yeshiva University. This noted legal scholar, who specializes in class actions and aggregate litigation, will share her insights into proposed MDL rule changes and legislative proposals to reform class actions. Catherine M. Sharkey, Crystal Eastman Professor of Law at the New York University School of Law. This learned educator will provide an overview and insights regarding the spate of high-impact appellate decisions that have been handed down recently in significant mass tort actions. "Judge Corodemus strives for excellence both in terms of the subject matter and the faculty for her annual event. Since her first program in 2010 she has remained devoted to [...]

News Release re Mass Torts Judicial Forum with Hon. Marina Corodemus (ret.)

March 17th, 2018|Categories: HB Tort Notes|Tags: Judge Corodemus, mass torts, news release, press release|

For Immediate Release Download in PDF Law Professors from NYU and Cardozo Among Panelists at Mass Tort Judicial Forum with Hon. Marina Corodemus (ret.) NEW YORK – MARCH 19, 2018 – Former New Jersey Superior Court Judge Marina Corodemus, now one of the nation's leading special masters for complex litigation, has selected two highly regarded law professors for the faculty of her annual event, Mass Torts Judicial Forum with Hon. Marina Corodemus (ret.), which will take place on April 23, 2018, in New York. Learn more. Press passes, interviews and program content are available to members of the press. Please contact Tom Hagy at (484) 324-2755 x2070 or write to him at tom.hagy@litigationconferences.com. The professors are: Myriam E. Gilles, Vice Dean and Paul R. Verkuil Chair in Public Law at the Benjamin N. Cardozo School of Law at Yeshiva University. This noted legal scholar, who specializes in class actions and aggregate litigation, will share her insights into proposed MDL rule changes and legislative proposals to reform class actions. Catherine M. Sharkey, Crystal Eastman Professor of Law at the New York University School of Law. This learned educator will provide an overview and insights regarding the spate of high-impact appellate decisions that have been handed down recently in significant mass tort actions. "Judge Corodemus strives for excellence both in terms of the [...]

‘Substantial Equivalence’ Ruling Presents a ‘Quandary’

March 17th, 2018|Categories: HB Tort Notes|Tags: 501(k), drug device defense, IVC, medical device, products liability, Reed Smith, substantial equivalence|

From the Drug & Device Defense Law Blog and a post by Reed Smith's Rachel B. Weil ... In In re Bard IVC Filters Prods. Liab. Litig., 2018 WL 1109554 (D. Ariz. Mar. 1, 2018), the court ruled on a number of motions in limine in advance of a mid-March trial. The plaintiff alleged that she was injured when defendant’s filter, inserted in her inferior vena cava (“IVC”) to capture blood clots, migrated and fractured. The filter that was implanted in the plaintiff, a Class II device, was granted 510(k) clearance by the FDA because of its “substantial equivalence” to an earlier filter model the defendant had marketed. And that is the source of the most interesting rulings. The ruling presents a quandary. We have spent many years defending manufacturers of Class 2 medical devices and advocating for admission of evidence of 510(k) clearance. We can appreciate the tension and the difficulty of drawing appropriate evidentiary lines. But evidentiary lines and regulatory requirements are different. This is a variant of the same fallacy underlying the 510(k) admissibility point discussed above. FDA regulatory requirements and admission of evidence in civil litigation are two different things, created for different purposes, and often don’t mix well. That is true here. For one thing, there is more to 510(k) than just substantial equivalence (“SE”). The entire relevant part [...]